These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20300981)

  • 1. Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype.
    Okada H; Toyoda Y; Takagi A; Saito H; Kojima T; Yamazaki T
    Int J Hematol; 2010 Apr; 91(3):549-50. PubMed ID: 20300981
    [No Abstract]   [Full Text] [Related]  

  • 2. Further evidence that activated protein C resistance affects protein C coagulant activity assays.
    Jennings I; Kitchen S; Cooper PC; Rimmer JE; Woods TA; Preston FE
    Thromb Haemost; 2000 Jan; 83(1):171-2. PubMed ID: 10669173
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of Factor V Leiden in three ethnic groups of patients with deep vein thrombosis in the Western Cape province of South Africa.
    Rubinstein R; Kolia F; Novitzky N
    Eur J Haematol; 2000 Jul; 65(1):78-9. PubMed ID: 10914945
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenotype and genotype expression in pseudohomozygous R2 factor V.
    Kalafatis M; Simioni P; Bernardi F
    Blood; 2001 Sep; 98(6):1988-9. PubMed ID: 11565539
    [No Abstract]   [Full Text] [Related]  

  • 5. Is homozygosity for the HR2 haplotype a risk factor for venous thromboembolism?
    Aras O; Hanson NQ; Tsai MY; Key NS
    Thromb Haemost; 2002 Jan; 87(1):173-4. PubMed ID: 11848451
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor V Leiden haplotypes in two homozygotes of Asian origin.
    Rees DC; Clarke K; Martin PG; Keeling DM
    Br J Haematol; 1998 Sep; 102(5):1381-2. PubMed ID: 9753076
    [No Abstract]   [Full Text] [Related]  

  • 7. The prevalence of factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in different human populations.
    Franco RF; Elion J; Tavella MH; Santos SE; Zago MA
    Thromb Haemost; 1999 Feb; 81(2):312-3. PubMed ID: 10064012
    [No Abstract]   [Full Text] [Related]  

  • 8. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):357-8. PubMed ID: 10959717
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor V Leiden in Mexico.
    Ruiz-Arguelles GJ
    Clin Appl Thromb Hemost; 2009; 15(3):366. PubMed ID: 19211579
    [No Abstract]   [Full Text] [Related]  

  • 10. Central retinal artery occlusion in a patient homozygous for factor V Leiden.
    Larsson J
    Am J Ophthalmol; 2000 Jun; 129(6):816-7. PubMed ID: 10927002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
    Luddington R; Jackson A; Pannerselvam S; Brown K; Baglin T
    Thromb Haemost; 2000 Feb; 83(2):204-8. PubMed ID: 10739373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of factor V Leiden and prothrombin 20210A mutations in indigenous Australians.
    Bennett JA; Palmer LJ; Musk AW; Erber WN
    Thromb Haemost; 2001 Dec; 86(6):1592-3. PubMed ID: 11776339
    [No Abstract]   [Full Text] [Related]  

  • 13. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
    Ma AD; Abrams CS
    Retina; 1998; 18(4):297-300. PubMed ID: 9730170
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
    Biswas A; Bajaj J; Ranjan R; Meena A; Akhter MS; Yadav BK; Sharma V; Saxena R
    Clin Chim Acta; 2008 Jun; 392(1-2):21-4. PubMed ID: 18342013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activated protein C resistance in the Japanese].
    Ozawa T
    Rinsho Ketsueki; 1996 Sep; 37(9):790-3. PubMed ID: 8914464
    [No Abstract]   [Full Text] [Related]  

  • 16. [One Chinese case of F V Leiden mutation associated with APC resistance].
    Wu J; Gu JM; Morrisey JH; Esmon N
    Zhonghua Xue Ye Xue Za Zhi; 1997 Sep; 18(9):453-6. PubMed ID: 15625834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Children with Legg-Perthes diseases.
    Pokharel RK; Matsuo M; Shiba R; Fujii S
    Clin Orthop Relat Res; 1999 Jun; (363):268-9. PubMed ID: 10379332
    [No Abstract]   [Full Text] [Related]  

  • 18. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor V variants, activated protein C resistance and venous thromboembolism.
    Simioni P; Kalafatis M; Manfrin D; Tormene D; Girolami A
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):661-2. PubMed ID: 9863717
    [No Abstract]   [Full Text] [Related]  

  • 20. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.